Metabolised by CYP3A4 but not a clinically significant inducer or inhibitor of any CYP450 isoenzymes. No indication of porphyrinogenic effects connected with the pharmacodynamic properties of the medicine.

Rupatadine is a selective histamine H1 receptor antagonist and platelet activating factor (PAF) antagonist.[DrugBank]

Rupatadine is used to treat allergic rhinitis. It is administered orally once-daily. [DrugBank]

Rupatadine is metabolised by oxidation, primarily mediated by CYP3A4, with CYP2C9, CYP2C19 and CYP2D6 involved to a lesser extent. [DrugBank] Its active metabolite desloratadine is considered probably not porphyrinogenic. Rupatadine was shown to inhibit CYP3A4, CYP2C19, CYP2D6 and CYP2E1 in human liver microsomes in vitro. However, these effects were at concentrations >100 times higher than the clinical Cmax, and inhibition at therapeutic concentrations is therefore not expected. [AUSPAR]